SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 12/11/18 Emmaus Life Sciences, Inc. 10-K 9/30/18 77:6.9M S2 Filings LLC/FA |
Document/Exhibit Description Pages Size 1: 10-K Annual Report HTML 930K 2: EX-10.13 Material Contract HTML 54K 3: EX-10.14 Material Contract HTML 53K 4: EX-10.15 Material Contract HTML 37K 5: EX-23.1 Consent of Experts or Counsel HTML 21K 6: EX-31.1 Certification -- §302 - SOA'02 HTML 26K 7: EX-31.2 Certification -- §302 - SOA'02 HTML 26K 8: EX-32.1 Certification -- §906 - SOA'02 HTML 22K 9: EX-32.2 Certification -- §906 - SOA'02 HTML 22K 16: R1 Document and Entity Information HTML 58K 17: R2 Consolidated Balance Sheets HTML 126K 18: R3 Consolidated Balance Sheets (Parenthetical) HTML 49K 19: R4 Consolidated Statements of Operations HTML 78K 20: R5 Consolidated Statements of Changes in Equity HTML 104K 21: R6 Consolidated Statements of Cash Flows HTML 119K 22: R7 Consolidated Statements of Cash Flows HTML 24K (Parenthetical) 23: R8 Nature of Operations HTML 32K 24: R9 Summary of Significant Accounting Policies HTML 90K 25: R10 Accounts Receivable, Net HTML 27K 26: R11 Long - Term Borrowings and Other Note Payables HTML 26K 27: R12 Acquisition HTML 47K 28: R13 Stockholders' Equity HTML 207K 29: R14 Convertible Preferred Stock HTML 39K 30: R15 Income Taxes HTML 67K 31: R16 Related Party Transactions HTML 29K 32: R17 Loss Per Share HTML 37K 33: R18 Commitments and Contingent Liabilities HTML 33K 34: R19 Significant Customers HTML 23K 35: R20 Subsequent Events HTML 32K 36: R21 Summary of Significant Accounting Policies HTML 165K (Policies) 37: R22 Summary of Significant Accounting Policies HTML 26K (Tables) 38: R23 Accounts Receivable, Net (Tables) HTML 28K 39: R24 Acquisition (Tables) HTML 46K 40: R25 Stockholders' Equity (Tables) HTML 176K 41: R26 Income Taxes (Tables) HTML 67K 42: R27 Loss Per Share (Tables) HTML 37K 43: R28 Commitments and Contingent Liabilities (Tables) HTML 28K 44: R29 Nature of Operations (Details Narrative) HTML 32K 45: R30 Summary of Significant Accounting Policies HTML 32K (Details ) 46: R31 Summary of Significant Accounting Policies HTML 31K (Details Narrative) 47: R32 Summary of Significant Accounting Policies HTML 71K (Details Narrative 1) 48: R33 Accounts Receivable, Net (Details) HTML 29K 49: R34 Long - Term Borrowings and Other Note Payables HTML 48K (Details Narrative) 50: R35 Acquisition (Details) HTML 67K 51: R36 Acquisition (Details 1) HTML 29K 52: R37 Acquisition (Details Narrative) HTML 57K 53: R38 Stockholders' Equity (Details) HTML 34K 54: R39 Stockholders' Equity (Details 1) HTML 27K 55: R40 Stockholders' Equity (Details 2) HTML 56K 56: R41 Stockholders' Equity (Details 3) HTML 123K 57: R42 Stockholders' Equity (Details 4) HTML 50K 58: R43 Stockholders' Equity (Details 5) HTML 34K 59: R44 Stockholders' Equity (Details 6) HTML 43K 60: R45 Stockholders' Equity (Details 7) HTML 63K 61: R46 Stockholders' Equity (Details Narrative) HTML 215K 62: R47 Stockholders' Equity (Details Narrative 1) HTML 101K 63: R48 Convertible Preferred Stock (Details Narrative) HTML 59K 64: R49 Income Taxes (Details) HTML 45K 65: R50 Income Taxes (Details 1) HTML 40K 66: R51 Income Taxes (Details 2) HTML 44K 67: R52 Income Taxes (Details 3) HTML 42K 68: R53 Income Taxes (Details Narrative) HTML 36K 69: R54 Related Party Transactions (Details Narrative) HTML 61K 70: R55 Loss Per Share (Details) HTML 48K 71: R56 Commitments and Contingent Liabilities (Details) HTML 25K 72: R57 Commitments and Contingent Liabilities (Details HTML 42K Narrative) 73: R58 Significant Customers (Details Narrative) HTML 31K 74: R59 Subsequent Events (Details Narrative) HTML 60K 76: XML IDEA XML File -- Filing Summary XML 131K 75: EXCEL IDEA Workbook of Financial Reports XLSX 100K 10: EX-101.INS XBRL Instance -- mynd-20180930 XML 1.87M 12: EX-101.CAL XBRL Calculations -- mynd-20180930_cal XML 199K 13: EX-101.DEF XBRL Definitions -- mynd-20180930_def XML 782K 14: EX-101.LAB XBRL Labels -- mynd-20180930_lab XML 1.28M 15: EX-101.PRE XBRL Presentations -- mynd-20180930_pre XML 1.00M 11: EX-101.SCH XBRL Schema -- mynd-20180930 XSD 198K 77: ZIP XBRL Zipped Folder -- 0001615774-18-014245-xbrl Zip 174K
Exhibit 31.2
Certification of Principal Financial Officer
Pursuant to SEC Rule 13a-14(a)/15d-14(a)
I, Donald D'Ambrosio, certify that:
1. | I have reviewed this Form 10-K of MYnd Analytics, Inc. for the fiscal year ended September 30, 2018; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a. | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b. | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c. | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d. | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5. | The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
a. | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
b. | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
December 11, 2018 | /s/ Donald D'Ambrosio |
Name: Donald D'Ambrosio | |
Title: Chief Financial Officer (Principal Financial Officer) |
C:
This ‘10-K’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed on: | 12/11/18 | None on these Dates | ||
For Period end: | 9/30/18 | |||
List all Filings |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/31/23 Emmaus Life Sciences, Inc. 10-K 12/31/22 88:18M Donnelley … Solutions/FA 3/31/22 Emmaus Life Sciences, Inc. 10-K 12/31/21 98:18M ActiveDisclosure/FA 8/10/21 Emmaus Life Sciences, Inc. 10-K/A 12/31/20 92:18M ActiveDisclosure/FA 5/04/21 Emmaus Life Sciences, Inc. 10-K 12/31/20 97:18M ActiveDisclosure/FA 1/25/21 Emmaus Life Sciences, Inc. 10-K 12/31/19 121:29M ActiveDisclosure/FA 5/30/19 SEC UPLOAD¶ 6/27/19 2:45K Emmaus Life Sciences, Inc. 5/02/19 SEC UPLOAD¶ 6/27/19 2:53K Emmaus Life Sciences, Inc. |